- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.04.2025 | 929 | Xetra Newsboard | Das Instrument 2NH ES0105043006 NATURHOUSE HEALTH EO-,05 EQUITY wird cum Kapitalmassnahme gehandelt am 02.04.2025 und ex Kapitalmassnahme am 03.04.2025 The instrument 2NH ES0105043006 NATURHOUSE HEALTH... ► Artikel lesen | |
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 08.01. | Sprint Bioscience AB: Sprint Biosciences upcoming activities | 120 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) summarizes below the company's upcoming meetings with potential partners and investors during the spring of 2025. In addition, the company will present at international scientific... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,910 | -16,23 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 62,76 | -1,88 % | Halozyme auf der Wells Fargo Conference: Strategisches Wachstum und Herausforderungen | ||
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| ABCELLERA BIOLOGICS | 3,618 | +0,56 % | AbCellera: Strategischer Schwenk zur eigenen Pipeline bei solider Finanzlage | ||
| GLOW LIFETECH | 0,032 | +1,59 % | Glow Lifetech Corp.: Glow Lifetech Reports 196% YoY Revenue Growth and Improved Cash Flow in Q2 2025, Sets Stage for Continued Momentum in H2 | Toronto, Ontario--(Newsfile Corp. - August 28, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the second... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 247,10 | -1,94 % | Bio-Rad auf Wells Fargo Konferenz: Strategisches Wachstum trotz Herausforderungen | ||
| BIOLINERX | 2,790 | -2,96 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,530 | -1,92 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,020 | 0,00 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results | FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
BURLINGTON, Mass., Aug. 14, 2025(Nasdaq:... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals, Inc.: Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) | Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10-million-patient marketAcquisition advances Paratek's vision... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,413 | +2,03 % | Applied Therapeutics Reports Second Quarter 2025 Financial Results | - CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,000 | -4,76 % | Ovid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties | NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs: Strategische Impfstoff-Entwicklungen und Finanzierungspläne vorgestellt | ||
| COCRYSTAL | 1,240 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs | Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen |
SPRINT BIOSCIENCE AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,035 Euro und damit +1,16 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.